Prostate cancer drug has side effects
Associated Press
/
February 7, 2012
Text size
–
+
Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects. The Food and Drug Administration will ask a panel of outside experts on Wednesday whether the benefits of Amgen’s Xgeva outweigh its risks, which included bone disease in about 5 percent of patients taking the drug. The agency posted its review of the drug online Monday morning ahead of the meeting.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
